EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, AVITA Medical's Enterprise Value is $184.52 Mil.
AVITA Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-39.46 Mil. Therefore, AVITA Medical's EV-to-FCF for today is -4.68.
The historical rank and industry rank for AVITA Medical's EV-to-FCF or its related term are showing as below:
RCEL'
s EV-to-FCF Range Over the Past 10 Years
Min: -45.36 Med: -13 Max: -1.44
Current: -4.68
During the past 13 years, the highest EV-to-FCF of AVITA Medical was -1.44. The lowest was -45.36. And the median was -13.00.
RCEL's EV-to-FCF is ranked worse than 100% of 362
companies
in the Medical Devices & Instruments industry
Industry Median: 27.855
vs RCEL: -4.68
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for AVITA Medical's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AVITA Medical's EV-to-FCF
For the Medical Devices subindustry, AVITA Medical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVITA Medical's EV-to-FCF Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where AVITA Medical's EV-to-FCF falls into.
AVITA Medical EV-to-FCF Calculation
AVITA Medical's EV-to-FCF for today is calculated as:
AVITA Medical's current Enterprise Value is $184.52 Mil.
AVITA Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVITA Medical (NAS:RCEL) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
AVITA Medical's PE Ratio for today is calculated as:
AVITA Medical's share price for today is $8.71.
AVITA Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.400.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
AVITA Medical EV-to-FCF Related Terms
Thank you for viewing the detailed overview of AVITA Medical's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
AVITA Medical (AVITA Medical) Business Description
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RCEL has been successfully added to your 